Biomarin Pharmaceutical INC (BMRN) — 8-K Filings

All 8-K filings from Biomarin Pharmaceutical INC. Browse 25 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (25)

BioMarin Pharmaceutical Files Current Report — Dec 22, 2025 Risk: low
On December 19, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing indicates that the report is a "Current Report" and is being filed pursuant t
BioMarin Pharmaceutical Inc. Files 8-K Report — Dec 19, 2025 Risk: low
On December 19, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and includ
BioMarin Pharma Reports Officer/Director Changes — Dec 17, 2025 Risk: medium
BioMarin Pharmaceutical Inc. filed an 8-K on December 17, 2025, reporting events as of December 11, 2025. The filing pertains to the departure of directors or c
BioMarin Pharmaceutical Inc. Files 8-K — Oct 27, 2025 Risk: low
On October 27, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations
BioMarin Pharmaceutical Inc. Files 8-K — Oct 7, 2025 Risk: low
On October 7, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition. No spe
BioMarin Pharma Announces Board & Executive Changes — Aug 11, 2025 Risk: low
BioMarin Pharmaceutical Inc. announced on August 5, 2025, changes in its board of directors and executive compensation. The filing details the departure of cert
BioMarin Pharmaceutical Inc. Files 8-K on Financials — Aug 4, 2025 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on August 4, 2025, reporting on its results of operations and financial condition. The filing includes financial state
BioMarin CFO Departs, New CFO Appointed — Aug 1, 2025 Risk: medium
BioMarin Pharmaceutical Inc. announced on July 30, 2025, the departure of its Chief Financial Officer, Jeffrey Robert, effective August 1, 2025. The company als
BioMarin Pharma Reports Director Changes and Officer Compensation Updates — May 22, 2025 Risk: low
On May 20, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a
BioMarin Pharmaceutical Inc. Files 8-K Report — May 16, 2025 Risk: medium
On May 16, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures
BioMarin Pharmaceutical Inc. Files 8-K on Financials — May 1, 2025 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
BioMarin Pharmaceutical Files 8-K on Security Holder Rights — Mar 3, 2025 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on March 3, 2025, reporting events as of February 25, 2025. The filing primarily concerns material modifications to se
BioMarin Appoints New Chief Medical Officer and EVP — Feb 24, 2025 Risk: medium
BioMarin Pharmaceutical Inc. announced on February 20, 2025, changes in its executive team. The company appointed Dr. Robert B. Baron as Chief Medical Officer a
BioMarin Pharmaceutical Inc. Files 8-K for Financial Reporting — Feb 19, 2025 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on February 19, 2025, to report on its results of operations and financial condition, as well as to file financial sta
BioMarin Pharmaceutical Inc. Files 8-K — Oct 29, 2024 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on October 29, 2024, to report on its results of operations and financial condition, as well as to file financial stat
BioMarin Pharmaceutical Inc. Files 8-K for Regulation FD Disclosure — Sep 24, 2024 Risk: low
On September 24, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure, indicating
BioMarin Pharmaceutical Inc. Enters Material Definitive Agreement — Sep 4, 2024 Risk: medium
On August 28, 2024, BioMarin Pharmaceutical Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company.
BioMarin Pharmaceutical Inc. Reports Exit/Disposal Costs — Aug 28, 2024 Risk: medium
On August 23, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify the
BioMarin Appoints New Chief Medical Officer and Controller — Aug 22, 2024 Risk: medium
BioMarin Pharmaceutical Inc. announced on August 16, 2024, changes in its executive team. The company appointed Dr. Jeffrey Robert, MD, PhD, as Chief Medical Of
BioMarin Pharmaceutical Inc. Files 8-K on Shareholder Votes — May 24, 2024 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on May 24, 2024, reporting on matters submitted to a vote of security holders on May 21, 2024. The filing details the
BioMarin Reports Exit/Disposal Costs — May 14, 2024 Risk: medium
BioMarin Pharmaceutical Inc. reported on May 9, 2024, that it is incurring costs associated with exit or disposal activities. The company has not disclosed spec
BioMarin Pharmaceutical Inc. Files 8-K on Financials — Apr 24, 2024 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on April 24, 2024, reporting on its results of operations and financial condition. The filing includes financial state
BioMarin CFO Resigns, Interim Appointed — Apr 23, 2024 Risk: medium
On April 9, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Brad Hauser, effective April 15, 20
BioMarin Files 8-K on Financial Condition and Operations — Feb 22, 2024 Risk: low
BioMarin Pharmaceutical Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition. The filing indicates that the co
BioMarin 8-K: Executive Compensation Arrangements Updated — Jan 11, 2024
BioMarin Pharmaceutical Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 5, 2024, related to changes in its executive compensa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX